Search

GlaxoSmithKline PLC

Fermé

SecteurSoins de santé

2,224 -1.64

Résumé

Variation du prix de l'action

24h

Actuel

Min

2178

Max

2264

Chiffres clés

By Trading Economics

Revenu

-1.5B

636M

Ventes

71M

8.6B

P/E

Moyenne du Secteur

15.712

110.024

BPA

0.255

Rendement du dividende

3.05

Marge bénéficiaire

7.38

Employés

68,629

EBITDA

-1.2B

2.2B

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

-10.94% downside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

3.05%

2.26%

Prochains Résultats

29 avr. 2026

Date du Prochain Dividende

9 avr. 2026

Date du Prochain Détachement de Dividende

19 févr. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

10B

88B

Ouverture précédente

2225.64

Clôture précédente

2224

Sentiment de l'Actualité

By Acuity

34%

66%

103 / 351 Classement par Healthcare

GlaxoSmithKline PLC Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

4 févr. 2026, 07:46 UTC

Résultats

GSK's Specialty Medicines Drive Solid Results

20 janv. 2026, 11:34 UTC

Principaux Mouvements du Marché
Acquisitions, Fusions, Rachats

RAPT Therapeutics Shares Jump Following Acquisition by GSK

20 janv. 2026, 10:40 UTC

Acquisitions, Fusions, Rachats

GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments -- Update

20 janv. 2026, 07:47 UTC

Acquisitions, Fusions, Rachats

GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments

4 févr. 2026, 13:12 UTC

Market Talk
Résultats

GSK Could Still Face U.S. Drug Pricing Headwind -- Market Talk

4 févr. 2026, 08:25 UTC

Market Talk
Résultats

GSK's Guidance Implies FX Headwind -- Market Talk

4 févr. 2026, 07:06 UTC

Résultats

GSK 4Q Core Operating Margin 19.0%

4 févr. 2026, 07:05 UTC

Résultats

GSK: 2031 Sales Outlook More Than GBP40B

4 févr. 2026, 07:03 UTC

Résultats

GSK Expects 2026 Core Operating Profit Growth of Between 7% to 9%

4 févr. 2026, 07:03 UTC

Résultats

GSK Expects 2026 Sales Growth of Between 3% to 5%

4 févr. 2026, 07:01 UTC

Résultats

Analysts Had GSK 4Q Core Operating Profit at GBP1.53B

4 févr. 2026, 07:01 UTC

Résultats

GSK 4Q Core Operating Profit GBP 1.63B

4 févr. 2026, 07:01 UTC

Résultats

Analysts Had GSK 4Q Sales at GBP8.495B

4 févr. 2026, 07:00 UTC

Résultats

GSK Issues 2026 View

4 févr. 2026, 07:00 UTC

Résultats

GSK PLC 4Q EPS 15.6p

4 févr. 2026, 07:00 UTC

Résultats

GSK PLC 4Q Adj EPS 25.5p

4 févr. 2026, 07:00 UTC

Résultats

GSK PLC 4Q Turnover GBP8.62B

4 févr. 2026, 07:00 UTC

Résultats

GSK PLC 4Q Pre-items, Pretax Pft GBP1.48B

4 févr. 2026, 07:00 UTC

Résultats

GSK PLC 4Q Oper Pft GBP1.1B

4 févr. 2026, 07:00 UTC

Résultats

GSK PLC 4Q Pretax Pft GBP950M

20 janv. 2026, 21:45 UTC

Acquisitions, Fusions, Rachats

This Biotech Stock Surges 64%. The Big Pharma M&A Battle Is Heating Up. -- Barrons.com

20 janv. 2026, 14:53 UTC

Acquisitions, Fusions, Rachats

This Biotech Stock Surges 64%. The Big Pharma M&A Battle Is Heating Up. -- Barrons.com

20 janv. 2026, 13:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

GSK's RAPT Deal Helps Address Looming Drug Patent Cliff -- Market Talk

20 janv. 2026, 13:28 UTC

Market Talk
Acquisitions, Fusions, Rachats

GSK's Deal to Buy RAPT Is the Right Risk -- Market Talk

20 janv. 2026, 12:10 UTC

Acquisitions, Fusions, Rachats

This Biotech Stock Surges 64%. The Big Pharma M&A Battle Is Heating Up. -- Barrons.com

20 janv. 2026, 07:15 UTC

Acquisitions, Fusions, Rachats

GSK Expects to Complete RAPT Buy in 1Q

20 janv. 2026, 07:15 UTC

Acquisitions, Fusions, Rachats

GSK: RAPT Buy Subject to Customary Closing Conditions

20 janv. 2026, 07:14 UTC

Acquisitions, Fusions, Rachats

GSK to Launch Tender Offer to Buy RAPT Common Stock Within 10 Business Days

20 janv. 2026, 07:14 UTC

Acquisitions, Fusions, Rachats

GSK: Ozureprubart Rights Exclude Mainland China, Macau, Taiwan, Hong Kong

20 janv. 2026, 07:13 UTC

Acquisitions, Fusions, Rachats

GSK Gets Global Rights to the Ozureprubart Program Under RAPT Deal

GlaxoSmithKline PLC prévision

Objectif de Prix

By TipRanks

-10.94% baisse

Prévisions sur 12 Mois

Moyen 1,928.21 GBX  -10.94%

Haut 2,450 GBX

Bas 1,500 GBX

Basé sur 15 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

15 ratings

3

Achat

8

Maintien

4

Vente

Sentiment

By Acuity

103 / 351Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
help-icon Live chat